OncoMatch/Clinical Trials/NCT03594422
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Is NCT03594422 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HQP1351 for gastrointestinal stromal tumor (gist).
Treatment: HQP1351 — This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastrointestinal Stromal Tumor
Tumor Agnostic
Biomarker criteria
Allowed: NF1 mutation
Allowed: SDHB deficient
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: imatinib (imatinib) — first-line
tumor progresses within 6 months first-line imatinib treatment
Must have received: tyrosine kinase inhibitor (imatinib)
imatinib or imatinib and at least one other TKI treatment failure (after imatinib or other TKI treatment for more than 6 months, tumor progress again after achieving tumor remission or stability)
Cannot have received: chemotherapy
Received any anti-cancer chemotherapy, biological agent treatment (e.g. Monoclonal antibody), immunotherapy (e.g. IFN) or radiotherapy with 28 days or 5 times half-time before first dose of HQP1351
Cannot have received: tyrosine kinase inhibitor
Received any TKIs within 14 days before first dose of HQP1351
Lab requirements
Blood counts
Adequate hematologic and bone marrow functions
Kidney function
Adequate renal function
Liver function
Adequate liver function
Cardiac function
Troponin(I/T) ≤ Upper Limit of Normal; Ejection fraction >40%; QTc interval ≤ 450 ms in male or ≤ 470 ms in female
Adequate hematologic and bone marrow functions. Adequate renal and liver function. Heart function index: Troponin(I/T) ≤ Upper Limit of Normal; Ejection fraction >40%; QTc interval ≤ 450 ms in male or ≤ 470 ms in female.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify